Are Inavolisib and Inavolisib the same drug?

Ihelai and Inavolisib (Inavolisib) are different Chinese names for the same drug. "Ihelai" is the trade name of the drug in mainland China, while "Inalise" is its international generic name. The two point to the same chemical molecule, GDC-0077, a selective PI3K alpha inhibitor mainly used to treat tumors such as breast cancer.

In China, Ihela is produced and sold by Gilead Sciences (Gilead Sciences ). The drug is currently in the clinical trial stage and has not yet been approved for marketing by the National Food and Drug Administration (NMPA). Therefore, patients cannot purchase the drug through formal channels in the country.

Internationally, Inavolisib (Inavolisib) is the international generic name of GDC-0077 and has been undergoing clinical trials in many countries and regions. The drug is mainly used to treat breast cancer patients with PIK3CA mutation-positive breast cancer, especially HR-positive and HER2-negative subtypes. Currently, Inariset has not been widely approved for marketing worldwide.

In short, Inavolisib and Inavolisib (Inavolisib) are different names for the same drug. Before considering using this drug, patients are advised to consult a professional doctor and pay attention to the latest announcements from relevant departments. With global medical progress and the improvement of China's drug approval system, the drug is expected to enter the Chinese market through approval in the future and may be included in the medical insurance system to reduce the financial burden on patients.

Reference materials:https://www.drugs.com/